Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Balversa - labeled renal guidance
Product / population
Erdafitinib (Balversa), adult oral tablets
Renal method
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
DailyMed SPL version 14, effective 2025-10-24; posted Nov 17, 2025
At eGFR 30-89 mL/min/1.73 m2, the label reports no clinically meaningful difference in exposure. Data in severe impairment are limited; PK during dialysis is unknown. These findings do not define a dialysis dose.
RDM73-balversa-official-1 · Source locator: Renal guidance: 12.3, specific populations
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
